09/16/2026

WPS Oncology Related LCD Updates

September Updates

September 2026 Local Coverage Determination (LCD) and Billing and Coding Article Updates

We updated the following Local Coverage Determinations (LCDs) and Billing and Coding Articles for September 2026. The full article on our website details additional information on these updates.  

Please note: Our LCDs and Billing and Coding/Coverage articles will reflect these changes on August 27, 2026.

New Policies/Articles – We created the following new policies/articles for September 2026 –Effective as Indicated: 

• Allergy Diagnostic Testing – Effective September 27, 2026
• Billing and Coding: Allergy Diagnostic Testing – Effective September 27, 2026
• Billing and Coding: MolDx: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer – Effective October 12, 2026
• MolDx: Genetic Testing for Hereditary Thrombophilia – Effective October 12, 2026
• MolDx: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer – Effective October 12, 2026
• Peripheral Nerve Blocks and Procedures for Chronic Pain – Effective October 25, 2026
• Response to Comments: Allergy Diagnostic Testing – Effective August 13, 2026
• Response to Comments MolDx: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer – Effective August 27, 2026
• Response to Comments: Peripheral Nerve Blocks and Procedures for Chronic Pain – Effective September 10, 2026

Retired Policies/Articles – We retired the following policies/articles for September 2026 – Effective September 26, 2026:

• Allergy Testing
• Billing and Coding: Allergy Testing

Revised Policies/Articles – We revised the following policies/articles for September 2026 –Effective as Indicated 

• Billing and Coding: MolDX: BCR-ABL – Effective August 27, 2026 
• Billing and Coding: MolDx: Biotheranostics Cancer Type ID® Update – Effective August 27, 2026 Billing and Coding: MolDx: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer – Effective August 6, 2026
• Billing and Coding: Non-Invasive Abdominal/Visceral Vascular Studies – Effective August 1, 2026